David Charles Lubner bought $1000K of Braveheart Bio (BRVE)
Executed Aug 7, disclosed Aug 7, the same day.
Over the 21 trading sessions from the disclosed entry session (Aug 7), the stock returned -10.0% (delay-adjusted); from the execution session (Aug 7), -10.0%. Derived: entry at the session's open, exit at the close 20 sessions later.
David Charles Lubner (Director) filed 2 Form 4 reports in the trailing twelve months (1 purchase, 1 sale), most often in ACLX. Across 1 priced purchase filing, the average 21-session return was -10.0% from execution and -10.0% from disclosure (delay-adjusted; derived). The largest single filing was $1000K of BRVE (55,555 sh × $18.00, as filed), executed Aug 7.
Healthcare · Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopat…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→